Morgan Stanley Maintains Equal-Weight on BioNTech, Raises Price Target to $111
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Korn has maintained an Equal-Weight rating on BioNTech (NASDAQ:BNTX) and raised the price target from $110 to $111.
November 08, 2023 | 8:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on BioNTech and raised the price target from $110 to $111, which could potentially influence the stock's performance.
The price target for BioNTech has been raised by Morgan Stanley, which indicates a positive outlook for the stock. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100